Media

The Media section provides reporters with easy access to Genentech information for stories in development. It also houses our recent and archived press releases.

Genentech Statements on Counterfeit Drug Labeled as Avastin® (bevacizumab) in the United States

Roche and Genentech have been informed by the FDA that counterfeit products, labeled as Avastin (bevacizumab) or Altuzan (bevacizumab), the brand name Roche sells Avastin under in Turkey, have been distributed illegally in the United States. Please see below for more information.

Read the statement from April 4, 2012 regarding Altuzan

Read the statement from February 14, 2012

Landmark Alzheimer's Prevention Trial
Genentech, the Banner Alzheimer's Institute, and the National Institutes of Health are collaborating on the first-ever prevention trial in cognitively healthy individuals who are likely to develop Alzheimer's disease due to their genetic history. Learn more

Genentech Medicine Approved For Advanced Basal Cell Carcinoma
On January 30, 2012, the FDA approved a Genentech medicine for the treatment of adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation. View information and materials on the approval

Genentech Medicine Approved For Certain Type Of Melanoma
On August 17, 2011, the FDA approved a Genentech medicine for a type of inoperable and metastatic melanoma. View information and materials on the approval